Any serious and/or unstable pre-existing medical, psychiatric, or other existing condition that would prevent compliance with the trial or consent process
Pre-existing Grade 2 or higher chronic diarrhoea
Pre-existing neuropathy greater than or equal to grade 2
Subjects with pre-existing grade II peripheral neuropathy
G>1 pre-existing peripheral neuropathy
Clinically significant peripheral neuropathy at the time of study entry. Patients with pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01
Pre-existing peripheral neuropathy Grade 2 or higher
Pre-existing neuropathy Grade 2 or higher
Severe pre-existing ototoxicity or neuropathy that would, in the opinion of the investigator, preclude the use of cisplatin chemotherapy
Serious pre-existing medical conditions as follows:
< Grade 2 pre-existing peripheral neuropathy per CTCAE
Patients with pre-existing grade >= 3 peripheral neuropathy
Patients with pre-existing peripheral neuropathy that would limit treatment with taxanes and platinum agents
Has pre-existing brain or bone metastatic lesions.
Skin condition\r\n* Patients with pre-existing grade 1 or higher ulcerations, fistulas, mucosal lesions, or skin barrier breakdown
Exclude patients with pre-existing neuropathy grade 2 or higher
Pre-existing and ongoing radiation-related grade 3 bowel or bladder toxicity
Patients must have < grade 2 pre-existing peripheral neuropathy (per CTCAE)
History of pre-existing immunodeficiency disorder, autoimmune condition, or chronic infection
Pre-existing peripheral neuropathy of grade II or higher
Pre-existing > grade 2 peripheral sensory neuropathy
Pre-existing sensory neuropathy of grade >= 2
Pre-existing grade 3 or 4 neuropathy
Pre-existing (active or severe) neurologic disorders (e.g. pre-existing seizure disorder)
Pre-existing viral hepatitis
Pre-existing neuropathy greater than grade 1
Patients with pre-existing retinopathy
Pre-existing peripheral neuropathy of severity grade >= 2 (limiting instrumental activities of daily living)
Pre-existing neuropathy of >= grade 2
Pre-existing grade >= 2 peripheral sensory neuropathy
Pre-existing vocal cord paralysis
Neurological assessment for pre-existing peripheral neuropathy
Patients with pre-existing grade 2 or greater peripheral neuropathy, defined as sensory alteration or paresthesia (including tingling), interfering with function
MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)
Pre-existing peripheral neuropathy CTCAE grade 2 or worse
Subjects with existing periorbital edema
Pre-existing peripheral neuropathy grade ?= 2 at registration
Pre-existing grade 2 or greater neuropathy
Patients with pre-existing grade 2 or higher neuropathy or other serious neurologic toxicity that would significantly increase risk of complications from bortezomib therapy are excluded
Pre-existing peripheral neuropathy > grade 2 with pain (CTC version 4.0).
Any known pre-existing autoimmune disorder
Pre-existing nephritic syndrome
Pre-existing grade >= 1 peripheral neuropathy
Pre-existing neuropathy of at least Grade 2
Has a pre-existing condition that is contraindicated including
Less than Grade 2 pre-existing peripheral neuropathy
Pre-existing neuropathy from any cause in excess of Grade 1.
Pre-existing peripheral neuropathy >= Common Terminology Criteria (CTC) grade 2 for those patients who received prior paclitaxel
Patients must have recovered from all reversible toxicities related to prior therapy before beginning protocol treatment, and may not have any pre-existing treatment-related toxicities greater than grade 2; patients must have < grade 2 pre-existing peripheral neuropathy
Patients must have < Grade 2 or pre-existing neuropathy (per CTCAE).
Pre-existing Grade greater than (>) 1 neuropathy
Pre-existing cardiac conditions
Side effects from prior treatment have not resolved to =< grade 1 (or baseline due to previously administered agent/pre-existing conditions)
Pre-existing peripheral neuropathy (grade I or higher)
Participant has received treatment with cytarabine for a pre-existing myeloid disorder.
Patients with Grade 2 or greater pre-existing neurologic abnormalities (CTCAE version 4.0), including Grade 2 or greater peripheral neuropathy caused by previous treatments.
Subjects with pre-existing grade 3 or 4 neuropathy; any peripheral neuropathy must recover to grade =< 1 before enrollment
Pre-existing grade 3 or 4 sensory neuropathy
Pre-existing neuropathy greater than grade 1
Pre-existing neuropathy greater than grade 1.
Pre-existing neuropathy grade III or greater
Pre-existing neuropathy from any cause in excess of Grade 1
Patients with pre-existing maculopathy or retinopathy of the eye
Pre-existing peripheral neuropathy >= grade 2
Existing autoimmune cytopenia
History of pre-existing post-traumatic stress disorder (PTSD)
Have serious pre-existing medical conditions.
Have serious pre-existing medical conditions (at the discretion of the investigator).
>= grade 2 pre-existing peripheral neuropathy (per CTCAEv4)
Pre-existing cancers and/or metastatic disease to the adrenal glands
Pre-existing peripheral neuropathy grade >= 2
Pre-existing neuropathy or severe fluid retention
Pre-existing peripheral neuropathy greater than CTCAE Grade 2.
Pre-existing >= grade 2 peripheral neuropathy
Patients with pre-existing neurologic toxicity > grade 1 (as per CTCAE version 3.0) are not eligible for participation in cohort A; patients screened for participation in cohort B with pre-existing neurologic toxicity > grade 2 (as per CTCAE, version 3.0) are not eligible, unless pre-existing neurologic toxicity is documented in detail and patient's participation in the trial has been approved by the neuro-oncology team at participating institutions
Pre-existing coagulopathy
Patient has pre-existing peripheral neuropathy Grade >1
Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).
Pre-existing symmetric peripheral painful neuropathy
Pre-existing LE prior to their BC diagnosis
Existing CVD
Patients with any pre-existing medical conditions that would be a contraindication to exercise
EXCLUSION - STUDY 1: Pre-existing neuropathy including CIPN from prior neurotoxic chemotherapy
History of pre-existing neuropathic pain conditions
Pre-existing neutropenia or neutrophil qualitative or quantitative disorder
Pre-existing cytopenia or bone marrow failure syndrome
Self-reported or documented history of pre-existing peripheral neuropathy due to diabetes, human immunodeficiency virus (HIV), or other conditions
Pre-existing active or untreated immunodeficiency disorder and/or chronic use of systemic steroids
Patients with pre-existing medical conditions that would be a barrier to exercise
Other identified causes of painful paresthesias existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing peripheral neuropathy of another etiology: e.g., carpal tunnel syndrome, B12 deficiency, acquired immune deficiency syndrome [AIDS], monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or hypothyroidism, inherited neuropathy, etc.) that might be responsible for the patient’s current neuropathic symptoms
SCREENING PHASE: Pre-existing peripheral neuropathy within 28 days of screening consent
INTERVENTION PHASE: Pre-existing peripheral neuropathy within 28 days of screening consent
Pre-existing grade 2 or greater neuropathy
History of pre-existing peripheral neuropathy prior to chemotherapy, including alcoholism, vitamin B deficiency, diabetes, human immunodeficiency virus (HIV), congenital neuropathy, toxic neuropathy
Pre-existing neuropathy, neuropathic pain, or nerve injury;
Pre-existing alopecia
Patient is using a pre-existing feeding tube for nutritional support at the time of study entry
Subject is using a pre-existing feeding tube for nutritional support at study entry.
Have pre-existing peripheral neuropathy from other medical conditions or due to cancer
Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of taxane chemotherapy
Pre-existing sensory neuropathy > grade 1